HLA-B27 frequency in a group of patients with psoriatic arthritis

Ruiz, Danilo Garcia; Azevedo, Mário Newton Leitão de; Lupi, Omar

doi:10.1590/s0365-05962012000600004

Cited by 15 publications

(8 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The association with psoriasis could reflect a diagnostic bias as patients with psoriasis and HLA‐B27 have a higher chance of being diagnosed by the rheumatologist and of being identified in their axSpA database. However, it could also reflect a true clinical association as was suggested in previous studies …”

Section: Discussionmentioning

confidence: 57%

HLA‐B27 prevalence in axial spondyloarthritis patients and in blood donors in a Lebanese population: Results from a nationwide study

et al. 2019

View full text Add to dashboard Cite

Aim:To calculate the prevalence of human leukocyte antigen (HLA)-B27 in axial spondyloarthritis patients (axSpA) compared to blood donors (BD) in Lebanon, to identify the clinical and radiological findings associated with HLA-B27 and to estimate the proportion of patients fulfilling the clinical arm of the Assessment of the Spondyloarthritis International Association (ASAS) criteria. Method:Consecutive Lebanese adult axSpA patients fulfilling the ASAS classification criteria were included from 12 rheumatology clinics across Lebanon. BD served as controls. A binary logistic regression was used to study the association between HLA-B27 and the disease features.Results: A total of 247 individuals were included (141 axSpA patients and 106 BD).The prevalence of HLA-B27 was 3.8% in BD and 41.1% in axSpA. Overall, 39.7% of the axSpA patients fulfilled the clinical arm of the ASAS classification criteria.Sensitivity of HLA-B27 for axSpA was 41.1%, specificity was 96.2%, positive predictive value was 93.6%, and negative predictive value was 55.13%. Positive likelihood ratio (LR) was 10.9 and negative LR was 1.63. We found a positive association of HLA-B27 with family history of SpA and psoriasis. Conclusion:Our study confirmed a low prevalence of HLA-B27 in axSpA patients and BD in this Lebanese population, However, we found a high specificity and positive LR, as well as the same number of axSpA patients fulfilling the clinical arm of the ASAS criteria as in European studies. HLA-B27 is therefore valuable for identification of axSpA in Lebanese patients despite the overall low prevalence in this population.Our results may guide future evaluations the role of HLA-B27 in planning local referral strategies.

show abstract

Section: Discussionmentioning

confidence: 57%

HLA‐B27 prevalence in axial spondyloarthritis patients and in blood donors in a Lebanese population: Results from a nationwide study

et al. 2019

View full text Add to dashboard Cite

show abstract

“…However, the role of genetic factors seemed to be less strong in Asians [23,[26][27][28]. Positive family history of PsO was found in approximately 15% of our patients, probably due to less prevalent HLA-B27 or other genetic predispositions in Hong Kong and Asia [20,[26][27][28]. A recent Japanese trial by Tanaka et al highlighted an even smaller percentage (4%) of PsA cohorts with a family history of PsO [23].…”

Section: Discussionmentioning

confidence: 91%

“…The PSOLAR study of 12,000 skin psoriasis patients in North and Latin America found that 45.5% and 10.3% of them had a positive family history of PsO and PsA, respectively [25]. However, the role of genetic factors seemed to be less strong in Asians [23,[26][27][28]. Positive family history of PsO was found in approximately 15% of our patients, probably due to less prevalent HLA-B27 or other genetic predispositions in Hong Kong and Asia [20,[26][27][28].…”

Section: Discussionmentioning

confidence: 99%

Clinical characteristics and comorbidities of psoriatic arthritis (PsA) in Hong Kong

Lai

Yim

Leung

et al. 2018

Hong Kong Bulletin on Rheumatic Diseases

View full text Add to dashboard Cite

Aim The primary objective of this study was to describe the clinical characteristics of psoriatic arthritis (PsA). The secondary objective was to evaluate the prevalence of various PsA comorbidities and their associated factors, with particular emphasis on metabolic syndrome (MetS). Methods Consecutive patients fulfilling the Classification Criteria for Psoriatic Arthritis (CASPAR) from two local hospitals were recruited between June 2016 and January 2018. Demographic data and related clinical parameters were collected and analyzed. MetS was defined by the International Diabetes Federation criteria for Asians. Results For the study, 201 eligible PsA patients were recruited: 124 were men and 77 were women. The mean age of onset of PsO and PsA was 36.6 ± 14.2 and 44.5 ± 12.6 respectively. Of the patients, 64.2% had central obesity, 18.4% had diabetes, 32.8% had hypertension and 35.8% had MetS. Univariate analysis showed that the (1) age onset of PsA, (2) PsA duration, (3) PsO duration, and (4) tender joint-count were the potential associative factors of MetS. Subsequent regression model identified that both age onset and disease duration of PsA were significantly associated with MetS, with p-values of 0.02 and 0.018, respectively. Older age of onset (46.5 ± 12.2 vs 43.4 ± 12.7 years) or longer disease duration (9.8 ± 8.4 vs 7.0 ± 6.7 years) of PsA increased the likelihood of developing MetS. No association of MetS was found with ESR or CRP levels, PASI, dactylitis count, enthesitis index, tender and swollen joint count, age onset of PsO and severe skin status. Conclusion PsA is a heterogeneous disease with an extremely diverse range of clinical features. It is also notably associated with other comorbidities, especially metabolic syndrome, in which it is closely related to arthritis onset and duration. In view of their common prevalence, regular screening of these PsA-related comorbidities is highly recommended.

show abstract

“…The high HLA-B27 positivity (90–95%) in AS patients suggests that HLA-B27 is strongly related to axial SpA. In contrast, the positivity is lower (22–36%) in PsA in which peripheral joints are mainly affected [ 11 , 12 ]. In addition, HLA-B27-positive PsA patients had a higher risk of axial involvement than did HLA-B27 negative PsA patients [ 13 ].…”

Section: Pathogenesismentioning

confidence: 99%

The Role of the IL-23/IL-17 Pathway in the Pathogenesis of Spondyloarthritis

Tsukazaki

Kaito

2020

IJMS

View full text Add to dashboard Cite

Spondyloarthritis (SpA) is a subset of seronegative rheumatic-related autoimmune diseases that consist of ankylosing spondylitis (AS), psoriatic spondylitis (PsA), reactive spondylitis (re-SpA), inflammatory bowel disease (IBD)-associated spondylitis, and unclassifiable spondylitis. These subsets share clinical phenotypes such as joint inflammation and extra-articular manifestations (uveitis, IBD, and psoriasis [Ps]). Inflammation at the enthesis, where ligaments and tendons attach to bones, characterizes and distinguishes SpA from other types of arthritis. Over the past several years, genetic, experimental, and clinical studies have accumulated evidence showing that the IL-23/IL-17 axis plays a critical role in the pathogenesis of SpA. These discoveries include genetic association and the identification of IL-23- and IL-17-producing cells in the tissue of mouse models and human patients. In this review, we summarize the current knowledge of the pathomechanism by focusing on the IL-23/IL-17 pathway and examine the recent clinical studies of biological agents targeting IL-23 and IL-17 in the treatment of SpA.

show abstract

HLA-B27 frequency in a group of patients with psoriatic arthritis

Cited by 15 publications

References 10 publications

HLA‐B27 prevalence in axial spondyloarthritis patients and in blood donors in a Lebanese population: Results from a nationwide study

HLA‐B27 prevalence in axial spondyloarthritis patients and in blood donors in a Lebanese population: Results from a nationwide study

Clinical characteristics and comorbidities of psoriatic arthritis (PsA) in Hong Kong

The Role of the IL-23/IL-17 Pathway in the Pathogenesis of Spondyloarthritis

Contact Info

Product

Resources

About